Naphazoline/pheniramine

Naphazoline/pheniramine
Combination of
PheniramineAntihistamine
Names
Trade namesNaphcon-A, Opcon-A, Visine-A, others
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    use
    Eye drop
    Defined daily dosenot established[1]
    External links
    AHFS/Drugs.comMultum Consumer Information
    Legal
    Legal status

    Naphazoline/pheniramine, sold under the brand name Naphcon-A among others, is a combination eye drop used to help the symptoms of allergic conjunctivitis such as from hay fever.[2] It contains naphazoline and pheniramine.[2][3] It is used as an eye drop.[3] Use is not recommended for more than three days.[4]

    Side effects may include allergic reactions, eye pain, and dilated pupils.[2][5][4] It is unclear if use in pregnancy is safe.[3] Nephazoline works by resulting in constriction of blood vessels thus decreasing redness well pheniramine works by blocking the effects of histamine to stop itching.[3]

    The combination was approved for medical use in the United States in 1994.[6][7][3] It is available over the counter.[6][7][2] In 2017, it was the 203rd most commonly prescribed medication in the United States, with more than two million prescriptions.[8][7]

    Medical use

    It is administered topically with one to two drops applied to the affected eye(s) up to four times daily.[2]

    Dosage

    The defined daily dose is not established[1]

    Side effects

    Society and culture

    Cost

    In 2017, it was the 203rd most commonly prescribed medication in the United States, with more than two million prescriptions.[8][7]

    References

    1. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 9 September 2020.
    2. 1 2 3 4 5 6 "Naphcon A- naphazoline hydrochloride and pheniramine maleate solution/ drops". DailyMed. 16 September 2019. Archived from the original on 28 August 2021. Retrieved 10 August 2020.
    3. 1 2 3 4 5 "Naphazoline and pheniramine ophthalmic Uses, Side Effects & Warnings". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019.
    4. 1 2 Kizior, Robert J.; Hodgson, Barbara B. (2014). Saunders Nursing Drug Handbook 2015 - E-Book. Elsevier Health Sciences. p. 163. ISBN 9780323280181. Archived from the original on 2020-04-16. Retrieved 2019-04-19.
    5. "Naphazoline/pheniramine ophthalmic Side Effects in Detail". Drugs.com. Archived from the original on 19 April 2019. Retrieved 19 April 2019.
    6. 1 2 "Naphcon-A: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 22 September 2020. Retrieved 19 April 2020.
    7. 1 2 3 4 "Naphazoline Hydrochloride; Pheniramine Maleate - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 11 April 2020.
    8. 1 2 "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.